TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02813967

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 54 Gy
Description: Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gy
Description: Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 70mg/m2 was administered on days 1-14 and 29-42.
Study: NCT03605160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional polish
Description: After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid-jet
Description: After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
Study: NCT00749216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Study: NCT01686165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study: NCT05081505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural exercise course
Description: 12-week structured exercise class, team competition, social support, and incentive strategy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomous group class
Description: 12-week autonomous group class, team competition, social support, and incentive strategy
Study: NCT01110083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1204831
Description: Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
Study: NCT04316728

Intervention type: DEVICE
Group type: OTHER
Intervention: VivaDiag™ COVID-19 lgM/IgG Rapid Test
Description: VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
Study: NCT02494921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV
Study: NCT02859467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping and Inhibitory Treatment Techniques
Description: Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Electrical Stimulation Therapy
Description: Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
Study: NCT03729921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric variceal ligation
Description: The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric variceal obturation
Description: Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
Study: NCT01551316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
Study: NCT04130334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
Description: After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: : After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
Description: : After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
Study: NCT01676532

Intervention type: OTHER
Intervention: Students attending SBHC
Description: School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
Study: NCT05516368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
Study: NCT01732146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin Beta
Description: erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02643719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abortive Medication (Naproxen and Sumatriptan)
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abortive Medication (Naproxen and Sumatriptan)
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
Study: NCT02416882

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise
Description: Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise
Description: Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary Option
Description: Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
Study: NCT03886519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BRAP (Bevel/rotate/advance procedure)
Description: Trichiasis surgery using the BRAP procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabut
Description: Trichiasis surgery using the Trabut procedure
Study: NCT02339324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and high dose interferon alfa-2b (HDI)
Description: Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
Study: NCT02377479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Taken for controlled ovarian hyperstimulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Taken for controlled ovarian hyperstimulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Taken for controlled ovarian hyperstimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Taken for controlled ovarian hyperstimulation
Study: NCT01766752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTab System
Description: Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
Study: NCT05285995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The animation intervention
Description: Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
Study: NCT02807012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing educational intervention
Description: The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access.
Study: NCT03067688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temisartan+Amlodipine+Rosuvastatin (Combination drug)
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temisartan+Amlodipine
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temisartan+Rosuvastatin
Description: PO, Once daily(QD), 8weeks
Study: NCT03734146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 180 minutes of moderate-vigorous intensity aerobic exercise per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 180 minutes of resistance exercise per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Description: 180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
Study: NCT03284489

Intervention type: OTHER
Intervention: Collection of medical datas from ICU patients
Description: Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
Study: NCT04741815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced Air Warming
Description: It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Carbon Fiber Warming
Description: It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
Study: NCT02253147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® RHA Ultra Deep
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles.
Study: NCT03317964

Intervention type: OTHER
Intervention: Saliva sample
Description: Extract sample of saliva only once

Intervention type: OTHER
Intervention: Saliva sample
Description: Extract sample of saliva only once
Study: NCT01064258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP at 4 cm H2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoCPAP
Description: autoCPAP working between 4 and 15 cm H2O
Study: NCT01640769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Image guided delivery of cardiac pacing leads.
Description: Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard delivery of cardiac pacing leads.
Description: Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
Study: NCT01871181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilioinguinal block
Description: 0.25% bupivacaine will be administered on a mg/kg basis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: Surgeon will infiltrate incision area with local anesthetic before closure.
Study: NCT01692249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate spa therapy
Description: , with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
Study: NCT03387228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain education
Description: Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking.
Study: NCT03596606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Treatment
Description: The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Treatment
Description: The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofunctional Motor control exercises
Description: The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises
Study: NCT02683252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1 mapping and MR perfusion acquisition
Description: One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1 mapping and MR perfusion acquisition
Description: One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1 mapping and MR perfusion acquisition
Description: One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1 mapping and MR perfusion acquisition
Description: One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1 mapping and MR perfusion acquisition
Description: One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
Study: NCT00851916

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Radiosurgery
Description: CyberKnife Radiosurgery